ProCE Banner Activity

TALAPRO-2: Phase III Trial of First-line Talazoparib + Enzalutamide in mCRPC

Capsule Summary
Conference Coverage

Talazoparib plus enzalutamide significantly improved median radiographic PFS vs placebo plus enzalutamide regardless of HRR gene alteration status as first-line therapy for patients with mCRPC.

Released: February 21, 2023

Expiration: February 20, 2024

Begin Activity


Provided by

ProCE Banner


This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.